Advanced search
Publication Cover
Acta Cardiologica Volume 62, 2007 - Issue 4
Submit an article Journal homepage
6
Views
0
CrossRef citations to date
0
Altmetric
Articles

Economic analysis of the use of drug-eluting stents from the perspective of Belgian health care

Joris MahieuFaculty of Applied Economics of the University of Antwerp, Belgium.Correspondence[email protected]
[email protected]
,
Annemieke De RidderFaculty of Applied Economics of the University of Antwerp, Belgium.
,
Diana De GraeveFaculty of Applied Economics of the University of Antwerp, Belgium.
,
Chris VrintsCardiology Department of the Antwerp University Hospital (UZA), Antwerpen, Belgium.
&
Johan BosmansCardiology Department of the Antwerp University Hospital (UZA), Antwerpen, Belgium.
Pages 355-365 | Received 21 Mar 2007, Accepted 11 May 2007, Published online: 23 May 2017

References

  • Van der Hoeven BL, Pires NMM, Warda HM, Oemrawsingh PV, van Vlijmen BJM, Quax PHA, Schalij MJ, van der Wall EE, Jukema JW. Drug-eluting stents: results, promises and problems. Int J Cardiol 2005; 99: 9–17.
  • Sousa EJ, Serruys PW, Costa MA. New frontiers in cardi-ology: Drug-eluting stents: Part I. Circulation 2003; 107: 2273–9.
  • Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004; 109: 1942–7.
  • Shafiq N, Malhotra S, Pandhi P, Grovera A, Uboweja A. A meta-analysis of clinical trials of paclitaxel- and sirolimus-eluting stents in patients with obstructive coronary artery disease. Br J Clin Pharmacol 2004; 59: 94–101.
  • Katritsis DG, Karvouni E, Ioannidis JPA. Meta-analysis comparing drug-eluting stents with bare metal stents. Am J Cardiol 2005; 95: 640–3.
  • Drug-Eluting Stent Update, Endovascular Today, May 2004, p. 28-29. Online available at: http://www.evtodayarchive.com/etart/et0504/et0504_update5.qxd%2040.pdf
  • Silber S. Which parameter should be chosen as primary end-point for randomized drug-eluting stent studies? J Interv Cardiol 2004; 17: 376–7.
  • Holmes DR, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, Wong SC, Midei M, Snead D, Kuntz RE. Analysis of 1-year clinical outcomes in the SIRIUS trial. Circulation 2004; 109: 634–40.
  • Cohen DJ, Bakhai A, Shi C, Githiora L, Lavelle T, Berezin RH, Leon MB, Moses JW, Carrozza JP, Zidar JP, Kuntz RE. Cost-effectiveness of Sirolimus-eluting stents for treat-ment of complex coronary stenoses. Circulation 2004; 110: 508–14.
  • Mahadeva H. Drug-eluting stents: Cypher vs. Taxus, IMS Health, last review on February 25, 2005, available online at: http://www.ims-global.com/insight/news_story/0502/news_story_050225.htm
  • Simpson SD. The stent wars continue, last review on March 8, 2005. Online available online at: http://www.fool.com/News/mft/2005/mft05030815.htm
  • Snider K. Medtronic stent to cut profit growth. China Daily, March 7, 2005. Online available at: http://www.chinadaily. com.cn/english/doc/2005-03/07/content_422367.htm
  • Wood S. Studies linking drug-eluting stents to increased mor-tality/MI spark impassioned pleas for reason and calls for calm. The Heart, September 3, 2006. Online available at: http://www.theheart.org/artic1e/736863.do
  • World Health Organisation (WHO), 2005(b), Prevalence of diabetes worldwide. Online available on http://www.who.int/diabetes/facts/world_figures/en/
  • Federaal Kenniscentrum voor de Gezondheidszorg, 2006, Voorlopige richtlijnen voor farmaco-economisch onderzoek in Belgi6. KCE Reports 2006: 28(a). Online available at: http://kce.fgov.be/index_nl.aspx?ID = O&SGREF = 5264&C REF = 6516 [in Dutch].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Committed to improving the lives of patients with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.
Bristol Myers Squibb – symposium on hypertrophic cardiomyopathy.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.